Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

2020/02/19 by Ning Tang, Dengju Li, Xiong Wang +1 · 12 citations
Medicine · #COVID-19 Clinical Research Studies #Sepsis Diagnosis and Treatment #Trauma, Hemostasis, Coagulopathy, Resuscitation

paper · pdf · doi:10.1111/jth.14768

openalex publication_date 2020/02/19 · crossref created 2020/02/19 · crossref issued 2020/04/01 · crossref published 2020/04/01 · crossref published-print 2020/04/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/27 · crossref indexed 2026/07/29 · openalex updated_date 2026/07/31

Citations

• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
• A Novel Coronavirus from Patients with Pneumonia in China, 2019
• Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
• Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
• La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19

Cited by

• Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19
• Pyroptosis: Physiological roles in viral infection
• Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
• Neutrophil extracellular traps in COVID-19
• Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
• The coming of age of neutrophil extracellular traps in thrombosis: Where are we now and where are we headed?
• Safety Monitoring of Multiple Health Outcomes Following 2023–2024 COVID-19 Vaccination among Medicare Beneficiaries Aged 65 Years and Older in the United States
• Hemostatic alterations in COVID-19
• Mechanisms of long COVID and the path toward therapeutics
• Can nebulised heparin reduce acute lung injury in patients with SARS‑CoV‑2 requiring advanced respiratory support in Ireland: the CHARTER‑Ireland phase Ib/IIa, randomised, parallel-group, open-label study
• Extrapulmonary manifestations of COVID-19
• Complement activation and endothelial perturbation parallel COVID-19 severity and activity